Table 2.
Characteristics of recurrence and secondary cytoreductive surgery
| Endometrial Carcinoma(N%) | Uterine Sarcoma(N%) | P-value | |
|---|---|---|---|
| Clinical symptoms at recurrence | 0.826 | ||
| None | 26 (55.3) | 19 (51.4) | |
| Symptomatic | 21 (44.7) | 18 (48.6) | |
| Ascites | 0.725 | ||
| No | 41 (87.2) | 34 (91.9) | |
| Yes | 6 (12.8) | 3 (8.1) | |
| Size of largest tumor (cm) | 0.001 | ||
| ≤ 6 | 41 (87.2) | 19 (51.4) | |
| > 6 | 6 (12.8) | 18 (48.6) | |
| Number of recurrent tumors | 0.186 | ||
| One | 24 (51.1) | 13 (35.1) | |
| Several | 23 (48.9) | 24 (64.9) | |
| Sites of recurrence | |||
| Central pelvis | 20 (42.6) | 27 (73) | |
| Lateral pelvis | 4 (8.5) | 11 (29.7) | |
| Pelvic lymphnodes | 5 (10.6) | 1 (2.7) | |
| Peritoneal dissemination | 10 (21.3) | 17 (45.9) | |
| Paraaortic lymphnodes | 7 (14.9) | 2 (5.4) | |
| Colon | 3 (6.4) | 7 (18.9) | |
| Small intestine | 1 (2.1) | 1 (2.7) | |
| Liver | 1 (2.1) | 0 (0) | |
| Adrenal gland | 1 (2.1) | 0 (0) | |
| Lung | 3 (6.4) | 2 (5.4) | |
| Chest wall mass | 0 (0) | 1 (2.7) | |
| Mediastinal lymph nodes | 1 (2.1) | 0 (0) | |
| Vaginal wall | 8 (17) | 1 (2.7) | |
| Vulva | 2 (4.3) | 0 (0) | |
| Inguinal lymphnodes | 1 (2.1) | 0 (0) | |
| Parietooccipital region | 1 (2.1) | 0 (0) | |
| Operative time, h (mean) | 2.85 ± 1.564 | 3.44 ± 1.308 | 0.072 |
| Intraoperative bleeding, ml (mean) | 237.23 ± 265.254 | 478.92 ± 594.978 | 0.015 |
| Haemoglobin drop, g/dl (mean) | 1.39 ± 1.213 | 2.12 ± 1.711 | 0.025 |
| Surgical procedures | |||
| Exploratomy laparotomy with biopsy | 2 (4.3) | 0 (0) | |
| Pelvic lymphadenectomy | 7 (14.9) | 4 (10.8) | |
| Colectomy | 7 (14.9) | 2 (5.4) | |
| Rectectomy | 4 (8.6) | 4 (10.8) | |
| Ileostomy | 1 (2.1) | 1 (2.7) | |
| Bladder resection | 0 (0) | 3 (8.1) | |
| Ureteral stents placement | 3 (6.4) | 7 (18.9) | |
| Ureterostomy | 0 (0) | 1 (2.7) | |
| Ureterovesical reimplantation | 2 (4.3) | 0 (0) | |
| Partial ureterectomy | 1 (2.1) | 0 (0) | |
| Reconstruction of bladder with ileum | 0 (0) | 1 (2.7) | |
| Pelvic mass resection | 6 (12.8) | 16 (43.2) | |
| Oophorectomy or oophorosalpingectomy | 2 (4.3) | 8 (21.6) | |
| Paraaortic lymphadenectomy | 10 (21.3) | 4 (10.8) | |
| Repair of vena cava injury | 1 (2.1) | 0 (0) | |
| Omentectomy or Peritoneal dissemination resection | 10 (21.3) | 17 (45.9) | |
| Small-bowel resection | 3 (6.4) | 3 (8.1) | |
| Partial hepatectomy | 1 (2.1) | 0 (0) | |
| Adrenal tumor resection | 1 (2.1) | 0 (0) | |
| Appendectomy | 2 (4.3) | 1 (2.7) | |
| Vaginectomy or Vaginal stump resection | 16 (34.0) | 4 (10.8) | |
| Diaphragmatic tumor resection | 1 (2.1) | 0 (0) | |
| Partial urethrectomy | 3 (6.4) | 1 (2.7) | |
| Subcutaneous mass excision | 1 (2.1) | 0 (0) | |
| Vulvectomy | 3 (6.4) | 0 (0) | |
| Inguinal lymph node resection | 1 (2.1) | 0 (0) | |
| Abdominal mass resection | 1 (2.1) | 2 (5.4) | |
| Chest wall tumor resection | 0 (0) | 1 (2.7) | |
| Pulmonary lobectomy | 2 (4.3) | 0 (0) | |
| Mediastinal lymphadenectomy | 1 (2.1) | 0 (0) | |
| Parietooccipital tumor resection | 1 (2.1) | 0 (0) | |
| Complications | |||
| None | 35 (74.5) | 28 (75.7) | |
| Bleeding | 0 (0) | 1 (2.7) | |
| Infection | 3 (6.4) | 4 (10.8) | |
| Intestinal fistula | 0 (0) | 1 (2.7) | |
| Urinary fistula | 1 (2.1) | 2 (5.4) | |
| Ileus | 3 (6.4) | 2 (5.4) | |
| Hydrothorax | 1 (2.1) | 0 (0) | |
| Lymphocyst | 1 (2.1) | 0 (0) | |
| Pelvic effusion | 0 (0) | 1 (2.7) | |
| Poor wound healing or herniation | 6 (12.8) | 1 (2.7) | |
| Thrombosis | 1 (2.1) | 0 (0) | |
| Hydronephrosis | 1 (2.1) | 0 (0) | |
| Peripheral neuropathy | 0 (0) | 1 (2.7) | |
| Complications that require surgery | |||
| No | 44 (93.6) | 34 (91.9) | 1.000 |
| Yes | 3 (6.4) | 3 (8.1) | |
| Length of hospital stays, day (mean) | 19.98 ± 6.883 | 24.84 ± 7.437 | 0.016 |
| Residual disease | 0.010 | ||
| None | 38 (80.9) | 20 (54.1) | |
| > 0 | 9 (19.1) | 17 (45.9) | |
| Neoadjuvent chemotherapy | 0.252 | ||
| No | 44 (93.6) | 37 (100) | |
| Yes | 3 (6.4) | 0 (0) | |
| Adjuvent therapy after SCS | |||
| None | 6 (12.8) | 10 (27) | |
| Chemotherapy only | 20 (42.6) | 20 (54.1) | |
| Radiotherapy only | 9 (19.1) | 2 (5.4) | |
| Combined chemoradiotherapy | 0 (0) | 2 (5.4) | |
| Hormonal therapy | 12 (25.5) | 2 (5.4) | |
| Other | 0 (0) | 1 (2.7) | |
| Recurrence | 0.001 | ||
| No | 21 (44.7) | 4 (10.8) | |
| Yes | 26 (55.3) | 33 (89.2) | |
| Death | 0.007 | ||
| No | 26 (55.3) | 9 (24.3) | |
| Yes | 21 (44.7) | 28 (75.7) |
SCS, Secondary cytoreductive surgery